Acute on Chronic Liver Failure
Conditions
Brief summary
All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016.ACLF (Acute on chronic Liver Failure). ACLF will be randomize into Group 1: MVP (Modest Volume Paracentesis) OF Less than 5 liters with IV albumin at a dose 8 gms/L of ascitic fluid Group 2: MVP (Modest Volume Paracentesis) of Less than 5 liters without albumin
Interventions
DRUGAlbumin
Intravenous albumin 8 gms/L of ascitic fluid
DRUGAscitic fluid
Sponsors
Institute of Liver and Biliary Sciences, India
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. All patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥ 5 mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease (ACLF) admitted in the hospital. 2. All Cirrhotics decompensated with ascites admitted in the hospital. 3. Grade II/III ascites 4. Need for paracentesis.
Exclusion criteria
1. Age \<12 or \> 75 years 2. Hepatocellular carcinoma 3. Non cirrhotic ascites such as malignancy or tubercular peritonitis 4. Serum Cr \>1.5mg% 5. Refractory septic shock 6. Grade III/IV hepatic encephalopathy 7. Abdominal wall cellulitis 8. Active variceal bleed 9. Respiratory, cardiac and renal failure 10. Refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total number of patients develop Circulatory Dysfunction because of paracentesis. | 1 Year |
Secondary
| Measure | Time frame |
|---|---|
| Survival | 28 days |
| Total number of patients develop hepatorenal Syndrome. | 1 Year |
| Total number of patients develop hyponatremia. | 1 Year |
| Changes in aldosterone with volume of ascitic fluid tap | 1 Year |
| Changes in plasma renin activity | 1 year |
Countries
India
Outcome results
None listed